Substrate-specific degradation is a key feature of the ubiquitin proteasome system. Substrate specificity is typically directed by the E3 or ubiquitin ligase; such specificity can be conferred either by ligase modification or expression or conversely via modification of substrates that permit their recognition by a specific E3 ligase. The most well-known example of such complexes are the Cullin-RING ligases (CRLs). CRLs are composed of one of seven cullin-family scaffold proteins; the CRL serves as a scaffold that interacts directly with a RING-domain enzyme (Rbx1/2) through an extensive protein-protein interface within the globular C-terminal domain. At the N terminus, the cullin associates with an adaptor protein through cullin-repeat motifs. This adaptor, in turn, facilitates recruitment of a substrate-specifying factor that recruits the target to be ubiquitylated. The prototypical CRL is the cul1-containing complex, commonly referred to as the Skp1-Cul1-Fbox (SCF) ligase. SCF ligases contribute to the timely destruction of numerous substrates thereby ensuring normal cell growth. The importance of SCF function is highlighted by cancer-specific alterations in either the expression or the function of select F-box substrate-specific adaptors that results in neoplastic conversion. Herein, we discuss the current understanding of SCF function and contribution to cell biology.
INTRODUCTION
Protein accumulation is the coordinate balance between synthesis and breakdown. Protein degradation is an essential cellular process that regulates the turnover of stable and highly labile polypeptides alike. Two major degradation mechanisms govern intracellular protein destruction: lysosomes and proteasomes. The ubiquitin-proteasome system (UPS) targets specific substrates for ATP-dependent digestion. Implicit in this distinction is the potential for dysregulation of specific substrates that contribute to cancer.
The UPS, as its name suggests, comprises two separate processes. In the first, the short 76 amino-acid peptide, ubiquitin (Ub), is conjugated to acceptor lysine residues on the substrate via the C-terminal Ub glycine (G76). The delivery of ubiquitin to substrate is carried out by its sequential transfer through several enzymes. The initial priming event of ubiquitylation begins with the ATP-dependent covalent attachment of ubiquitin to an E1 ubiquitin-activating enzyme. The E1-ubiquitin intermediate facilitates spontaneous transfer of Ub to an E2 ubiquitinconjugating enzyme. At this juncture, one of two potential pathways is chosen, although both result in substrate ubiquitylation. In one scenario, the E2-Ub species, directed by RING domain E3 ubiquitin ligases to the target, is poised to deliver the Ub posttranslational modification directly to substrates. Alternatively, the Ub-conjugated E2 enzyme associates with and passes off the Ub molecule to a HECT domain E3 ubiquitin ligase for direct transfer from thioester-linked Ub-E3 to substrate. Ultimately, through either mechanism, substrates receive the ubiquitin modifier through the coordinate actions of the cascade of ubiquitinassociated enzymes. Although our emerging understanding of the function of protein ubiquitylation has broadened to include cell signaling and trafficking, UPS-dependent proteolysis remains a major, if not the major role of ubiquitin modification. Importantly, the distinction between ubiquitin as a signal transduction event and as a mark for proteolysis results from differences in poly-ubiquitin linkages. Although mono-ubiquitylation or K63-linked polyubiquitylation is associated with its role as an intracellular signal, addition of a chain of four or more ubiquitin molecules through lysine 48 of ubiquitin (K48 polyubiquitin) facilitates targeting to the 26S proteasome. Although proteasome targeting by Skp1-Cul1-Fboxs (SCFs) in this review largely focus on K48-linked chains, evidence indicates that other mechanisms, such as K11 polyubiquitylation, also contribute to the degradation pathway. 1, 2 Substrate-specific degradation is a key feature of the UPS. Therefore, it should not be surprising that the human genome encodes more than 300 RING domain-containing polypeptides, each responsible for the surveillance of certain target proteins. In some instances, additional substrate selectivity is conferred by multi-unit complexes wherein the RING ubiquitin ligase associates with separate components that direct substrate recruitment. Perhaps the most well-known example of such complexes are the Cullin-RING ligases (CRLs). CRLs contain a cullin-family scaffold protein, which interacts directly with the RING-domain enzyme through an extensive protein-protein interface within the globular C-terminal domain. At the N terminus, the cullin protein associates with an adaptor protein through cullin-repeat motifs. This adaptor, in turn, facilitates recruitment of a substrate-specifying factor that recruits the target to be ubiquitylated. The prototypical CRL is exemplified by the Cul1-containing complex, commonly referred to as the SCF ligase.
Within SCFs, Rbx1 serves as the RING-containing enzyme, Cul1 is the Cullin scaffold, and Skp1 is an adaptor, which serves to link the F-box substrate-specific factor to the rest of the ligase (Figure 1 ). In all, 7 cullins (Cul1, 2, 3, 4a, 4b, 5, 7) and 69 F-box-encoding genes have been identified in humans. 3, 4 Although the majority of advances in our understanding of CRLs are derived from SCFs, the general mechanisms discovered with the SCF paradigm will likely serve to broaden our knowledge of all CRLs. In this review, we place the significant findings of the past 10 years relating to SCF function into context, particularly with emphasis on cell cycle regulation and tumorigenesis.
REGULATION OF SCFS
SCFs are critical regulators of key cell signaling nodes and are particularly important in cell cycle regulation with dysregulation resulting in major oncogenic consequences. Thus, in turn, regulation of SCF activity is critical. In the past decade, multiple paradigms of regulating SCF activity have emerged.
First, neddylation of SCFs with the small ubiquitin-like modifier Nedd8/RUB1 at the C-terminal tail of Cul1 enhances association with RING E3 ligases, thereby increasing SCF activity. In 2008, Saha and Deshaies reported that in addition to E2 enzyme recruitment, which is the primary mechanism by which Nedd8 enhances ubiquitin chain elongation, neddylation helps to bring the B50 Å gap between the substrate and E2 for transfer of the first ubiquitin molecule. 5 Like ubiquitylation, Nedd8 delivery requires an E1 (NAE) and E2 (Ubc12) enzyme. 6 Neddylation of Cul1 is directed by Dun1D1 (SCCRO). 7, 8 Specifically, Dun1D1, although not required, enhances neddylation by recruiting Ubc12 to the Cul1-CAND1-Rbx1 complex. 9 The activity of Dun1D1 is important for the nuclear localization and has an impact on cellular proliferation as demonstrated in knockout fibroblasts. Conversely it is well established that de-neddylation is facilitated by the large octameric complex COP9 signalosome (CSN). 10 The isopeptidase activity within CSN is conferred by the metalloenzyme-containing CSN5 subunit. 11 In 2003, Doronkin et al. provided proof-ofprinciple demonstration of the inhibitory effect of CSN on SCFmediated cyclin E degradation using CSN5 mutants. 12 Although CSN serves to block SCF function in vitro, some in vivo data suggest that CSN actually promotes degradation of SCF substrates. 13 This apparent paradox was originally thought to result from a requirement for CSN in SCF assembly and stability. In 2005, He et al. reported that CSN mutants stabilize the FWD-1 substrate FRQ, thereby regulating the circadian clock in neurospora.
14 Furthermore, mutation of CSN resulted in low levels of FWD-1 and increased turnover. More recent evidence suggests that substrate binding itself ejects CSN from SCF complexes and promotes neddylation. [15] [16] [17] In addition to CSN, Cul1 is regulated by CAND1; binding of CAND1 prevents Cul1 association with Skp1 and evidence suggests that neddylation executes its positive regulation of SCFs at least in part through promoting CAND1 dissociation, thereby enhancing SCF assembly. 18, 19 Indeed, the crystal structure of CAND1-Cul1-Roc1 demonstrates that CAND1 adopts a superhelical structure that buries the Skp1-binding site of Cul1. Furthermore, the lysine residue that accepts neddylation is shrouded by the presence of two CAND1 HEAT repeats, consistent with the notion of competitive inhibition between Nedd8 and CAND1. 20 On the flip side, a recent crystal structure report indicates that the Rbx1-binding protein glomerulin adopts HEAT-like folds that preclude Rbx1-Cul1 interactions, and loss of this interaction likely contributes to the vascular lesions seen in glomuvenous malformation. 21 Although SCF assembly is clearly regulated, SCF disassembly also appears to be an active process. Stress-induced recruitment of the ATPase Cdc48/p97 to yeast SCF Met30 physically dissociates the F-box component from the complex, and blocks substrate ubiquitylation. 22 Regulation of SCFs also occurs directly through F-box proteins. One mechanism is through dimerization of the entire complex, mediated through D domains, typically at the N terminus of F-box proteins. Mutations in the D domains of Fbw7 and Fbx4 exhibit dimerization deficiency and fail to regulate substrates. 23, 24 b-TrCP1 or b-TrCP2 homodimers, but not heterodimers, form active ligases toward IkB. In the case of Fbx4, a cell cycle-dependent GSK3-b phosphorylation event within the D domain serves as a docking site for 14-3-3b, which in turn facilitates dimerization. 25 Finally, WD40 repeats, which define Fbw proteins, have been proposed to bind directly to ubiquitin, thereby effecting their own turnover and auto-destruction. Interestingly, mutation of the ubiquitinbinding domain in Cdc4 (Fbw7) affect some functions, while preserving others, indicating the presence of both ubiquitinbinding-dependent and -independent functions. In aggregate, emerging data over the past decade indicate that regulation of substrate proteolysis not only occurs at the substrate level but also involves intricate mechanisms controlling SCF activity.
SCF CDC4/CDC34 ACCOMMODATES MULTIPLE GEOMETRIES
Lys48-linked polyubiquitin chains mark the conjugated protein for degradation. In many instances, multiple polyubiquitin chains are initiated on multiple lysine residues within a given substrate. Although the use of multiple internal acceptor lysines was not considered of functional relevance, the differential role of internal substrate lysines in facilitating protein turnover is now appreciated. Using Sic1 as a model substrate and SCF Cdc4/Cdc34 as the E3 ligase, Petroski and Deshaies demonstrated in 2003 that a singlepolyubiquitin chain is sufficient to preserve physiological turnover, but different lysine acceptor sites confer significantly different proteolytic rates. 26 Furthermore, binding of Sic1 to S-CDK influences the cast of lysines that are ubiquitylated. Finally, SCF Cdc4/Cdc34 is capable of polyubiquitylation of Sic1 at any of the lysine residues, with chains 6-20 Ub in length. Given that the gap between Cdc34 and Sic1 is thought to span B50 Å, and the theoretical length of ten Ub's being 130 Å, the major implication is that SCF Cdc4/Cdc34 must somehow accommodate numerous geometries to delivery ubiquitin to sites that are relatively remote on a macro-molecular scale. Further insights on this topic came with the demonstration that Nedd8 modification of Cul1 facilitates the bridging of E2 to substrate. 27, 28 Indeed, small-angle X-ray diffraction revealed that SCF Cdc4 forms a homotypic dimer around the N-terminal dimerization domain. 29 This results in a SCF dimer in which the substrate-binding WD40 domains and the E2 catalytic sites lie in a single plane with 'a separation of 64 Å within and Figure 1 . The Skp1-Cul1-Fbox ubiquitin ligase complex. The RINGcontaining Roc1 (Rbx1) E3 ligase interacts with the Cul1 scaffold protein. At the opposite terminus, Cul1 associates with the Skp1 adaptor, which in turn recruits the F-box substrate specificity factor. The F-box protein recognition of substrates brings the latter into the proximity of Roc1 for ubiquitin delivery.
102 Å between each SCF monomer,' perhaps explaining a role for the gap between enzyme and substrate, and accommodation of long poly-Ub chains. These data provide a paradigm by which multiple SCFs likely operate; b-TrCP and Fbx4, among others, as well as the non-SCF E3 ligases such as APC/C complexes, 30 are also known to be activated by dimerization.
PROCESSIVITY AND TIME-SCALE OF POLYUBIQUITYLATION
A long-standing question in the UPS field concerns whether substrate polyubiquitylation occurs sequentially or whether preformed polyubiquitin chains are directly delivered to substrates. In 2009, Pierce et al. provided new metholodogies to address this age-old question and provide evidence that polyubiquitylation can occur sequentially on the substrate on a millisecond time scale. 31 In addition, the processivity of polyubiquitylation owes in part to the rapid, dynamic assembly/disassembly of E2-E3 complexes, as a result of electrostatic interactions between the acidic tail of Cdc34 and a basic 'canyon' within the C terminal of Cul1.
RATE-LIMITING STEP IN POLY-UBIQUITYLATION
The geometries accommodated by SCF Cdc4/Cdc34 dimers may facilitate a wide range of substrate sterics, however, the ratelimiting step in ubiquitylation remains conjugation of the first ubiquitin. 32 Although mono-ubiquitylation is relatively slow, elongation of a K48-linked chain proceeds quickly. A model to explain this was proposed wherein a conserved acidic loop within Cdc34 facilitates K48-linked processivity but has no impact on catalysis of the first ubiquitin. 32 Additional evidence for this model was provided using Cdc34 mutants and molecular modeling with Sic1/SCF Cdc4/Cdc34 to suggest that E2 dissociation is not required for ubiquitylation and substrate turnover. 33 Thus, the actual mechanism(s) responsible for the rate-limiting determinant of the first ubiquitin remain somewhat contentious. Interestingly, a 'priming/extending hand-off' mechanism occurs with one E2 enzyme catalyzing the first ubiquitylation event and another E2 enzyme facilitating extension of the polyubiquitin chain. 34 Specifically, SCF b-TrCP/UbcH5 efficiently mono-ubiquitylates the IkBa substrate, whereas subsequent poly-ubiquitylation is enhanced by SCF b-TrCP/Cdc34 . Furthermore, the regulation of mono-versus poly-ubiquitylation has biological consequences and physiological significance, specifically with regard to transcriptional regulation. The SRC-3 growth co-activator is phosphorylated and mono-ubiquitylated, thereby enhancing SRC-3 coactivator function. Extension of this ubiquitylation event makes SRC-3 susceptible to 26S-mediated degradation. Thus, this sequence of post-translational modifications serves as a 'transcriptional time clock.' GLOBAL SUBSTRATE IDENTIFICATION APPROACHES Although over 500 E3 ligases have been identified, only a small fraction of these have identified substrates associated with them. 35 Traditional approaches have been successful but are also limited by the dynamics of substrate recognition. In 2008, a new strategy, utilizing global protein stability profiling, combined with either microarray deconvolution or enhanced green flourescence protein (EGFP)-fused open reading frame (ORF) screening permitted a novel large-scale approach to substrate identification. 36 Of the 350 putative substrates identified, several were known SCF targets and many were previously unknown targets. Several years later, work from the same laboratory combined global protein stability profiling with another novel approach, termed 'Quantitative Ubiquitylation Interrogation', which is based on mass spectrometry using stable isotope labeling with amino acids in cell culture. With these technologies, nearly 500 proteins regulated by CRLs were identified. 37 Future studies employing these protocols will greatly facilitate our understanding of dynamic protein degradation at a system biology level.
NON-CANONICAL SUBSTRATE MODALITIES
Although conventional substrate recognition by SCF complexes is typically mediated through a phospho-degron motif, as observed for cyclins D1, E and b-catenin, several reports have proposed noncanonical substrate recognition mechanisms. For example, Fbx2 recognizes N-linked high mannose oligosaccharides, thereby contributing to degradation of glycosylated proteins based on this modification. 38 Fbx2 can associate with cystic fibrosis transmembrane conductance regulator and regulate its cellular accumulation. However, as Fbx2 is primarily expressed in neurons, the potential of defects in this pathway to contribute to neurological or neurodegenerative pathologies requires further consideration.
In 2002, Noureddine et al. demonstrated that substrate recruitment is not confined to the F-box components of SCFs. In Drosophila, the F-box protein Slimb facilitates proteolysis of Cubitus interruptus as well as armadillo. 38 Expression of Roc1 mutants resulted in Cubitus interruptus accumulation, but not armadillo, suggesting that Slimb associates with another E2 enzyme, which targets armadillo but not Cubitus interruptus. These studies present intriguing alternate mechanisms to SCF function, however, there is a relative paucity of studies further addressing non-canonical substrate recognition modalites in the past 10 years. Periodic re-evaluation of SCFs will likely facilitate more discoveries of unconventional mechanisms of action.
F-BOX SUBSTRATE ADAPTORS AND THEIR SUBSTRATES Fbw7
Over the past decade, overwhelming evidence has emerged supporting a role for Fbw7 as a human tumor suppressor. 39, 40 In 2001, Koepp et al. identified Fbw7 as the SCF specificity factor responsible for directing cyclin E degradation. 41 The crystal structure of Fbw7-Skp1-cyclin E reveals that high affinity substrate-Fbw7 interactions depend upon a dual phosphorylation event at T380 and S384. 42 Biochemical analyses demonstrate a similar requirement for Sic1, a substrate of the yeast Cdc4-based SCF, which contains three dual phosphorylation sites separated by three residues. Adding an extra layer of complexity, cyclin E ubiquitylation requires the sequential action of distinct Fbw7 isoforms. 43 First, Fbw7a recruits cyclin E and the prolyl isomerase Pin1, without directly ubiquitylating cyclin E. Isomerization of a non-canonical proline-proline bond is thought to facilitate subsequent ubiquitylation by Fbw7g. More recent work suggests that prolyl isomerase Pin1 also disrupts Fbw7 dimerization, facilitates its auto-ubiquitylation and turnover. 44 Although Fbw7 deletion in the mouse is embryonic lethal, mice heterozygous for Fbw7 on a p53 compromised backgrounds demonstrate that it is a haploinsufficient tumor suppressor, with a tumor spectrum including lung, liver and ovarian cancer. 45 Although loss of Fbw7 has been proposed to contribute to tumorigenesis through the generation of genetic instability via Aurora A activation 45 and cyclin E stabilization, 46 this specific genotoxic stress effect is not clearly understood and warrants further investigation.
Regardless, it is clear that Fbw7 mutations in human cancer contribute to cyclin E overexpression. 47 In addition, the in vivo relevance of phosphorylation-dependent cyclin E turnover was bolstered by knock-in mouse models with alanine substitutions at the phospho-degron sites. These mice accumulate cyclin E in various tissue and suffer from abnormal erythropoiesis and epithelial hyperplasias, consistent with faulty cell cycle regulation. 48 Mammary epithelial cells exhibit increased apoptosis, perhaps relating to chromosomal instability conferred by loss of Fbw7-dependent cyclin E regulation. 46 An independent group also utilizing mice with bone marrow deficient in Fbw7 found similar phenotypes involving defects in hematopoiesis; however, cyclin E accumulation was absent in their study, although myc was stabilized.
Myc is another well-documented oncogenic Fbw7 substrate. 49, 50 Like cyclin E, Fbw7 degradation of c-myc relies upon a dual phosphorylation motif (Mycbox I-containing T58 and S62). SCF recruitment of substrates typically facilitates its ubiquitylation and degradation. In the case of MYC, however, reports suggest more intricate substrate-enzyme interactions. For example, Fbw7a bridges the interaction between MYC and the de-ubiquitylating enzyme USP28, thereby serving a seemingly contradictory function in stabilizing MYC. 51 If this is the case for Fbw7a, more than likely, this model will apply to other F-box proteins. With regard to N-myc-driven neuroblastomas, N-myc-activated Aurora A kinase functions in a positive feedback loop through binding to N-myc and ultimately interfering with Fbw7-dependent degradation of the transcription factor. 52 This paradigm, wherein substrates influence expression of factors that prevent its SCFdependent degradation, is worth further exploration. Finally, ubiquitylation at the N terminus of myc by b-TrCP antagonizes Fbw7-dependent ubiquitylation through the formation of N-terminal non-K48-linked heterotypic ubiquitin chains; these marks not only stabilize myc but are also required for myc activation and myc-dependent post S-phase cell cycle acceleration. 53 Thus, ubiquitylation events at distinct lysine sites by different SCF ligases can result in dramatically different outcomes.
Also one of the canonical Fbw7 substrates, Notch1, is frequently overexpressed in T-cell acute lymphoblastic leukemia. 54 Strikingly, screening of T-cell acute lymphocite leukemia (T-ALL) samples and cell lines revealed an Fbw7 mutation rate of B30%, resulting in stabilized Notch1. 55 Of note, the role of these insults as driver mutations is strongly supported by animal studies. Conditional murine Fbw7 deletion in the hematopoietic compartment initially leads to HSC depletion via p53-dependent apoptosis (likely a result of dysregulated cycling and chromosome instability); ultimately, however, T-ALLs develop in these mice. 56 Recently, our understanding of the consequences of Fbw7 inactivation in T-ALL have been broaden to include stabilization of the prosurvival Bcl-2 family member MCL1. Importantly, Fbw7 mutant cells were resistant to a Bcl-2 antagonist, indicating that the relationship between Fbw7 status and MCL1 expression appears to predict sensitivity to therapy. 57 In addition, anti-tubulin chemotherapeutics potential mitotic cell death that is dependent on MCL1 depletion at this cell cycle phase; patientderived tumor cells with Fbw7 genetic insults are significantly more resistant to taxol and vincristine. 58 However, loss of Fbw7 is not a pro-survival event in all contexts. One of the earlier identified Fbw7 substrates, c-Jun, accumulates in the absence of Fbw7 and stimulates AP-1-dependent apoptosis. 59 More recently, Fbw7-dependent stabilization of p100 in multiple myeloma was discovered to suppress nuclear factor kB (NF-kB)-mediated apoptosis. 60 In in vitro and in xenograft models, Fbw7 silencing led to NF-kB-induced apoptosis. Thus, future characterization of the effect of Fbw7 inactivation will necessitate exploration of the relative effects on pro-apoptotic and prosurvival pathways in each cellular context. Other noteworthy Fbw7 targets identified in the past decade, with potentially important tumorigenic implications, include KLF5, PGC-1a and SREBP. [61] [62] [63] b-TrCP Also a member of the WD40-repeat family of F-box proteins, btransducin-repeat containing protein (b-TrCP aka Fbw1) has long been known to promote SCF-mediated degradation of several key molecules governing major signaling pathways, including IkB in the NF-kB pathway, b-catenin in the Wnt pathway and Emi1 in APC/C regulation. Similar to Fbw7, b-TrCP interacts with a specific dually phosphorylated degron (DSGjXS, where j is a hydrophobic residue and X is any residue). The crystal structure of bTrCP in complex with Skp1 and a b-catenin peptide has been solved; 64 the structure suggests that the mechanism of action of b-TrCP was to increase the effective concentration of substrate lysines in the vicinity of E2 enzymes and also provide a basis for the selection of lysines within the substrate for ubiquitin conjugation.
The consequences of b-TrCP1 deletion in the mouse are mainly manifest as a reduction in male fertility with a corresponding accumulation of metaphase I-arrested spermatocytes. 65 Depletion of b-TrCP2 by inducible small hairpin RNA on a b-TrCP1 knockout background results in a severe testicular phenotype marked by a near absence of spermatids and meiotic cells. 66 Intriguingly, the transcriptional regulator Snail1 was upregulated in these mice and Snail1 depletion reversed the testicular phenotype. However, rigid biochemical evidence that Snail1 is a bona fide b-TrCP substrate is lacking.
In addition to the b-TrCP-dependent Snail1 and Emi1 mitotic regulators, xenopus oocyte studies also identified RINGO as a critically regulated b-TrCP substrate that instead of undergoing degradation, is processed to a truncated form, mediating G2 arrest. 66 Also of particular interest, ubiquitylation at the N terminus of myc by b-TrCP via UbcH5 actually stabilizes the substrate through the formation of N-terminal non-K48-linked heterotypic ubiquitin chains. This heretofore undescribed mechanism represents a potential paradigm, wherein cell cycle regulators are processed in an SCF-proteasome-dependent manner and subsequently degraded via a distinct E3 ubiquitin ligase.
Several novel functions for b-TrCP have been published with oncogenic implications. First, although ARF is the classic allosteric inhibitor of the p53 ubiquitin ligase Mdm2, recent evidence suggests that b-TrCP also promotes casein kinase I-dependent Mdm2 turnover, implicating b-TrCP as a tumor suppressor. Loss of b-TrCP or CKI leads to accumulation of Mdm2, decreased p53 activity and resistance to DNA damage in transformed human cells. 67 Whether alterations in this pathway upstream of p53 regulation occur in p53-intact tumors remains to be seen. In addition to Mdm2, CKI-dependent phosphorylation of the negative Hippo regulator and oncogene YAP also primes it for b-TrCP-mediated degradation. 68 However, data supporting a role for Hippo/YAP/CKIb-TrCP axis in driving tumorigenesis in animal models or clinical samples are lacking and requires further investigation.
Another potential tumor suppressor function of b-TrCP was uncovered through its interactions with DEPTOR. 69, 70 DEPTOR is an inhibitor of the well-known Akt effector, mammalian target of rapamycin; depletion of b-TrCP results in an accumulation of DEPTOR, which in turn activates autophagy and enhances cell survival upon nutrient deprivation. Thus, b-TrCP suppression could potentially contribute to cancer through dysregulation of the CKI targeted-oncogenes Mdm2 and YAP as well as through DEPTORdependent induction of autophagy. In light of these reports, outlining the oncogenic effects of b-TrCP silencing, the fact that inactivating b-TrCP mutations are rarely seen in human cancer is somewhat surprising. Although sporadic mutations are found in a few malignancies, including breast cancer, more often, b-TrCP is intact and highly expressed. 71 Supporting a role for b-TrCP as a pro-proliferative effector, mouse models expressing exogenous b-TrCP develop mammary hyperplasia. 72 Other lines of evidence exist assigning an oncogenic function to b-TrCP. RE1-silencing transcription factor (REST) expression maintains stemness in neural progenitor cells and is often highly expressed in de-differentiated medulloblastomas and neuroblastomas. REST also inhibits Mad2 expression, necessary for the integrity of the spindle assembly checkpoint in mitosis. REST contains a conserved phospho-degron, and has been identified as a substrate of b-TrCP. Cells expressing a REST mutant incapable of binding b-TrCP exhibits an identical phenotype to Mad2-deficient cells, primarily resulting from faulty spindle checkpoint. 73 In human mammary epithelial cells, b-TrCP overexpression causes cellular transformation and this phenotype is REST dependent. 18 At the other end, Cul1 interacts with Skp1-Skp2, placing the Rbx1 and Skp1-Skp2 subunits B100 Å apart, one of the first reports to suggest that Cul1 scaffolding between the ubiquitylating conjugation enzyme and the substrate-affinity subunit facilitates ubiquitin delivery. Supporting this notion, mutations inducing Cul1 rigidity abrogate ubiquitylation activity of the enzyme.
Like b-TrCP and Fbw7, Skp2 dimerization constitutes an active SCF ligase. Also like Fbw7, Skp2 is phosphorylated; Skp2 phosphorylation, however, has not been described to directly enhance dimerization. Rather, Skp2 is phosphorylated by Akt on S72, and this phosphorylation event enhances SCF Skp2 activity. 77 In addition, Skp2 phosphorylate serves as a docking site for the regulatory protein 14-3-3b. This association relocalizes Skp2 to the cytosol, where it appears to have a role in cell migration in human cancers.
Unlike b-TrCP and Fbw7, Skp2 requires an additional co-factor Cks1 for recognition of its prototypical substrate, p27. 78 Cks1, greatly enhances phosphorylation-dependent Skp2 turnover. Structural data indicate that binding of Cks1 to Skp2 is mediated through the leucine-rich region of the C-terminal tail. Phosphorylation of T187 on p27, in turn, is recognized by a Cks1-binding site, which controls its Cdk2-cyclin A-mediated turnover. These insights furthered the notion that SCFs are regulated at several different levels. Thus, with regard to SCF regulation, in addition to phosphorylation-dependent dimerization seen with Fbw7, the Skp2/Cks1 interaction provides an instance, wherein F-box activity is regulated through protein-protein interaction. Furthermore, Skp2 is regulated by active degradation in G1 phase by the APC/C(Cdh1) complex. Cdh1 depletion, as well as a Skp2 mutant unable to bind APC/C(Cdh1), confers premature S phase entry supporting the critical role of Skp2 in governing cell cycle progression. 79, 80 As mentioned, one of the first identified and arguably most important cell cycle machinery substrates is the CDK inhibitor, p27. 81 Loss of Skp2 in mice results in severe proliferation defects and abnormal cell size and DNA content, whereas these phenotypes are reversed on a p27-deleted background, thus establishing that Skp2 degradation is required for cell cycle progression. On the other hand, ectopic expression of Skp2 alone in mouse prostate promotes hyperplasia, dysplasia and low-grade carcinoma. 82 In addition, in mammary carcinoma models, ectopic ErbB2 expression induces Skp2 with reduction in p27 levels. 83 These pro-tumorigenic effects may be in part due to the suppression of senescence programs. Specifically, Skp2 appears to inhibit cellular senescence in a ARF/p53-independent manner; rather Skp2 directly opposes the activity of p27, p21 and the transcription factor ATF4. 84 However, other reports have questioned this role; p27 degradation proceeds even in the absence of Skp2. 85 Data from the Nakayama lab indicate that a distinct ubiquitin ligase, termed Kip1 ubiquitination-promoting complex, localizes to the cytoplasm and ubiquitylates p27. 86 The role of Skp2 on cell cycle progression has been demonstrated through p27-independent pathways as well. For instance, SCF Skp2 directly ubiquitylates the phospho-672 form of the p130 pocket protein. 87 Rb also associates with Skp2, although the function of this interaction was reported to disrupt Skp2-p27 complexes. 88 The clinical significance of these interactions was demonstrated in estrogen receptor-positive breast cancers, wherein anti-estrogen therapy downregulated Cks1 and restored p130/Rb levels. Conversely, estradiol upregulated Cks1 and decreased p130/Rb. 89 Recently published evidence implicates Skp2 in the regulation of Akt signaling. Whereas TRAF6 ubiquitylates Akt in response to IGF1 stimulation, ErbB2 activation leads to Skp2-dependent Akt activation. Skp2 deficiency results in impaired Akt activation and glucose metabolism. These data suggest that modulating ubiquitin ligases such as Skp2 may impact the efficacy of Herceptin treatment on Her2-positive breast cancers.
Mixed lineage leukemia (MLL), an S phase checkpoint effector, is dysregulated in poor prognostic leukemias. SCF Skp2 promotes MLL turnover in S phase. 90 Phosphorylation of MLL by ataxia telangiactasia and Rad3 related (ATR), initiated by a checkpoint response, disrupts MLL-Skp2, thereby stabilizing it. Although chromosomal translocations disrupt MLL expression, future studies should address whether Skp2 upregulation is sufficient to drive MLL depletion and, hence, impaired S-phase checkpoint response.
Many other Skp2 substrates have been identified with novel implications in cancer biology. The Skp2 substrate Tob1 opposes cell cycle progression by suppression cyclin D1 expression, thus representing another mechanism to control the G1/S transition. 91 Yet another cell cycle-dependent function of Skp2 was uncovered in the unexpected discovery that the V(D)J recombinase RAG2 is specifically degraded by SCF Skp2 in S phase. 92 In addition, although other human origin recognition complex (hORC) subunits are stable, hOrc1p levels accumulate following M phase, and are rapidly degraded as cells enter S phase. Destruction of hOrc1p occurs in part through SCF Skp2;
. 93 Thus, SCF Skp2 is implicated in multiple critical G1/S and S-phase processes.
Fbx4
Although Skp2, b-TrCP and Fbw7 have received the most attention in the SCF literature in the past decade, the F-box family includes roughly 70 members, many with less extensively explored functions. One of these, Fbx4 is intriguing for several reasons. First, Fbx4 is responsible for regulating the critical cell cycle switch cyclin D1. Cyclin D1 overexpression is a major oncogenic event and seen in a wide variety of carcinomas and leukemias. Although most descriptions of cyclin D1-related oncogenic hits have focused on gene amplification, translocations and direct insults, the contribution of impaired degradation has become increasingly apparent. Lack of Fbx4 in vivo predisposes to tumor formation. Second, compared with the other aforementioned F-box proteins, a relative paucity of Fbx4 substrates have been identified. Other than cyclin D1, only telomere repeat factor 1 (TRF1) has been shown to be subject to Fbx4-directed ubiquitylation. Given the ability of F-box substrate interacting domains to interact with phospho-degrons, it is very likely that multiple unidentified substrates remain to be discovered. Third, regulation of Fbx4 combines many of the similarities shared with other members of the family. These regulatory events include phosphorylation-dependent dimerization, 14-3-3 association and activation, and co-factor recruitment for substrate-specific interaction.
Fbx4 was first identified as an F-box protein that associates with a co-factor aB crystallin, a member of the small heat-shock protein family. 94 Though its substrates were not initially determined, it was established that aB crystallin enhances Fbx4 ubiquitylation in a manner reminiscent of the Skp2/Cks1 interaction. Binding of aB crystallin occurs through the C-terminal substrate binding domain of Fbx4. Phosphorylation of aB crystallin on S19 and S45 facilitate docking to Fbx4. 94 In 2006, both cyclin D1 and Pin2/TRF1 were identified as Fbx4 substrates. 95, 96 Interestingly, the binding of aB crystallin to Fbx4 is required for cyclin D1 recruitment but is dispensable for Pin2/TRF1 interaction. Decreased aB crystallin and/or Fbx4 expression has been observed in human esophageal and breast cancers and melanoma. 24, 95, 97 Analogous to Fbw7, phosphorylation-dependent dimerization is a critical step that governs Fbx4-directed SCF ligase activity. GSK3-b phosphorylation of Fbx4 S12 creates a consensus phospho-docking 14-3-3b site at the N terminus. With Skp2, 14-3-3b binding serves to redistribute cellular localization; however, Fbx4/14-3-3b complexes do not relocalize.
Mutations in the Fbx4 dimerization domain impair its activity in human esophageal cancer, resulting in cyclin D1 accumulation. Instead, 14-3-3e binding promotes Fbx4 homo-dimerization, and thus activity. 25 Mutations such as S8R and S12L disrupting this 14-3-3 interacting site exist in Fbx4 derived from human esophageal cancer. Furthermore, mutations in the cyclin D1 phospho-degron site, which is required for both nuclear export and Fbx4 recognition, have also been observed. 98 The implications of Fbx4 dysregulation with regard to Pin2/TRF1 are less clear in the context of cancer. This substrate acts as both a component of the shelterin complex (TRF1) that shields telomeres from telomerase and as a critical mitotic regulator (Pin2). 96, 99, 100 Pin2/TRF1 is often downregulated in human cancers, suggesting a tumor suppressor function; however, evidence that this is a causative/contributory oncogenic process is lacking. Although Pin2/TRF1 deletion in the mouse is embryonic lethal, conditional knockouts in stratified epithelia still die perinatally but result in skin hyperpigmentation and dysplasia. Placed on a p53-compromised background, survival is rescued but squamous cell carcinomas are observed, arguing for a TRF1 tumor suppressor role. In the hematopoietic compartment, deletion of TRF1 leads to bone marrow failure and mimics dyskeratosis congenita. 101 The Fbx4 mutations found in human cancer are inactivating and result in cyclin D1 and TRF1 accumulation. Although a large body of literature details the oncogenic effects of cyclin D1 overexpression, relatively scant evidence supports a role for elevated TRF1 levels in cancer. The transforming potential of Fbx4 deletion is critically dependent on the presence of cyclin D1; however, formal evidence to address whether it is also TRF1 dependent is lacking. 24 Fbx4 knockout mice are viable and fertile, but succumb to a variety of malignancies, most commonly lymphoma. 102 The development of lymphoma is remarkably similar to the phenotype seen in mice expressing a non-degradable cyclin D1 mutant in the lymphocytic compartment. 103 Parenchymal tissue, tumor samples and mouse embryonic fibroblasts exhibit elevated cyclin D1, higher rates of proliferation and increased S phase population. Thus, based on human cancer tissue, bolstered by an animal model, Fbx4 is a tumor suppressor that critically regulates the cyclin D1 proto-oncogene.
CONCLUSIONS
In the past decade, an extensive amount of research has been dedicated to further our understanding of CRLs and in particular SCF ubiquitin ligases. Novel global screening approaches will likely facilitate the ease and rate with which new targets are identified. These strategies are particularly important as it is apparent that F-box proteins typically regulate numerous substrates; oftentimes, these substrates have opposing effects on tumorigenesis (for example, b-TrCP), making in vivo deletion difficult to interpret. In addition, the substrates of the majority of F-box proteins remain unknown and many important ubiquitin-degraded cell cycle proteins have not been assigned a ligase or only weak evidence exists in the literature. Future systematic and comprehensive studies will be needed to address these unidentified connections and their implications in the biology of human cancer, combining the approaches and the collectively acquired knowledge of the previous decade.
